McKesson Corporation – 2026-02-05 - Increase Confidence 7/10

MCK – Predicted Increase in Days/Weeks

McKesson’s Q3 revenue surged 11.4% YoY to $106.16B, with EPS of $9.34 beating estimates. The company has also raised its full-year EPS guidance and made strategic acquisitions to bolster its high-growth oncology segment.

Why This Matters

In a low-margin, high-volume distribution business, consistent top-line growth and operational efficiency are paramount. McKesson’s ability to exceed earnings expectations and raise guidance demonstrates strong execution and pricing power in a stable, essential industry. The strategic moves into oncology services, a higher-margin and growing market, provide a tangible catalyst for future earnings growth, making the stock attractive to investors looking for defensive yet growth-oriented names in the near term.

Key Insights

• Financial Performance: Q3 Revenue of $106.16B (+11.4% YoY) and EPS of $9.34 (beat).
• News Impact: Management raised full-year adjusted EPS guidance, signaling confidence in ongoing performance.
• Risk/Offset: The stock trades at a forward P/E of ~21.7, which is not cheap and leaves little room for execution missteps.

Practical Implications

• Bull Case: Continued momentum from raised guidance and positive sector trends pushes the stock toward its recent 52-week high of ~$972.
• Bear Case: The stock’s premium valuation could limit upside if broader market sentiment sours, potentially causing a pullback to recent support levels.
• Confidence: 7/10 – Strong fundamentals and positive guidance are clear near-term drivers, though the valuation is a headwind.

Prediction: increase

Reference:

• From internal analysis.